Sun Pharmaceutical Industries Limited announced that it has received final approval from US FDA for its Abbreviated New Drug Application for generic Mesalamine Extended Release Capsules, 500 mg. The generic product approval is based on Pentasa Extended Release Capsules, 500mg as a reference product.